---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-066057"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2023-05-30T23:59:59+00:00"
generated_at: "2026-06-14T11:25:51.557527+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Annual meeting results: Patel elected, compensation and auditor approved

## Summary
- Elected Dinesh V. Patel as Class I director with 32,660,198 for, 8,874,076 withheld, 3,298,693 broker non-votes.
- Advisory executive compensation approved: 39,838,516 for, 1,673,050 against, 22,708 abstentions, 3,298,693 broker non-votes.
- Ratified Ernst & Young as independent auditor for FY2023: 44,807,871 for, 15,794 against, 9,302 abstentions.

## SEC filing metadata
- accession: 0001104659-23-066057
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2023-05-30T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465923066057/0001104659-23-066057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465923066057/tm2317329d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-066057
- JSON: https://secwatch.observer/filing/0001104659-23-066057.json
- Plain text: https://secwatch.observer/filing/0001104659-23-066057.txt

## Key facts
- Shareholder Votes
  Protagonist Therapeutics, Inc shareholders approved To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-25 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-25
  source text: Proposal 3 — To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 44,807,871 15,794 9,302 --
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465923066057/0001104659-23-066057-index.htm
- Shareholder Votes
  Protagonist Therapeutics, Inc shareholders approved To approve, on an advisory basis, the compensation of the Company’s named executive officers. at the 2023-05-25 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-25
  source text: Proposal 2 — To approve, on an advisory basis, the compensation of the Company’s named executive officers. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 39,838,516 1,673,050 22,708 3,298,693
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465923066057/0001104659-23-066057-index.htm
- Shareholder Votes
  Protagonist Therapeutics, Inc shareholders approved Election of Class I director nominee Dinesh V. Patel at the 2023-05-25 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-25
  source text: Proposal 1 — To elect the Class I director nominee named below to serve until the 2026 Annual Meeting of Stockholders and until his successor has been duly elected and qualified. Dr. Dinesh V. Patel was elected, with the votes thereon as follows: Final Voting Results Nominee For Withheld Broker Non-Votes Dinesh V. Patel, Ph.D. 32,660,198 8,874,076 3,298,693
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465923066057/0001104659-23-066057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.